Welcome to our dedicated page for Keen Vision Acquisition news (Ticker: KVAC), a resource for investors and traders seeking the latest updates and insights on Keen Vision Acquisition stock.
Keen Vision Acquisition Corporation is a Nasdaq-listed blank-check company formed to pursue a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. News about KVAC centers on its SPAC status, business-combination process, material agreements, sponsor and capital-structure actions, shareholder-vote matters, and governance disclosures. The company has described its search focus as biotechnology, consumer goods and agriculture opportunities evaluated with sustainability, environmental, social and corporate governance considerations.
Medera announced the publication of a study in Pharmacological Research demonstrating how its subsidiary Novoheart is using AI and machine learning to enhance drug screening with human mini-Heart technology. The study achieved an 86.2% predictive accuracy in classifying drug effects, addressing the challenge of high failure rates (over 90%) in clinical trials that result in development costs exceeding $2 billion per drug. The innovative approach combines AI/ML with multiple human mini-Heart screening assays to improve drug classification capabilities, potentially reducing costs and enhancing safety in drug development.
Medera announced completion of Cohort A and initiation of Cohort B dosing in its MUSIC-HFpEF Phase 1/2a clinical trial, evaluating SRD-002, a first-in-human gene therapy for Heart Failure with Preserved Ejection Fraction (HFpEF). The trial shows promising efficacy results at six months in Cohort A (low-dose 3x10^13 vg), with no unexpected events or toxicities. Following DSMB recommendation, Cohort B (high-dose 4.5x10^13 vg) enrollment has begun. The company expects to complete Cohort B enrollment in Q1 2025, with interim data expected in H1 2025. HFpEF affects nearly half of 64.3 million heart failure cases worldwide, with treatment options available.
Keen Vision Acquisition Corp (NASDAQ: KVAC) is subject to a stockholder investigation by Monteverde & Associates concerning its proposed merger with Madera Inc. Under the merger agreement, Keen Vision common stock will be canceled and converted into the right to receive a number of Madera common stock.
The law firm invites eligible shareholders to learn more and contact them at no cost or obligation. The announcement highlights the firm’s experience recovering money for shareholders and suggests shareholders ask firms about prior recoveries and courtroom experience before hiring counsel.
Medera Inc., a clinical-stage biotechnology company, is set to be listed on NASDAQ through a merger with Keen Vision Acquisition (KVAC). The combined entity will have an initial enterprise value of approximately $622.6 million. Medera focuses on developing next-generation gene- and cell-based therapies for difficult-to-treat cardiovascular diseases. The transaction proceeds will accelerate Medera's three most advanced clinical programs for AAV-based gene therapy candidates.
Key highlights include:
- Medera's founders and key shareholders have committed $22.6 million
- All existing Medera shareholders are rolling 100% of their equity
- A closing condition requires Medera to have at least $40 million in available liquidity
- The merger is expected to close in Q4 2024
This NASDAQ listing aims to advance Medera's clinical and preclinical programs, potentially expediting the development of novel therapeutic solutions for patients with unmet needs.
Medera and special purpose company Keen Vision Acquisition Corporation (KVAC) agreed to merge, with the combined company to list on Nasdaq under the name Medera upon closing expected in Q4 2024. The transaction implies an initial enterprise value of approximately $622.6 million. Cash proceeds may include up to $149.5 million from KVAC's trust account (before stockholder redemptions). Medera founders and key holders committed roughly $22.6 million via conversion of shareholder loans, and existing Medera shareholders will roll 100% of their equity. A closing condition requires Medera to have at least $40 million in available liquidity.
Clinical programs: Sardocor operates three AAV cardiac gene-therapy trials: SRD-001 (HFrEF; Phase 1/2a; 6 low-dose and 1 high-dose patients dosed; Phase 1/2a completion expected Q4 2024), SRD-002 (HFpEF; Phase 1/2a; 5 patients dosed; cohort B cleared; enrollment expected complete end of 2024; interim readout H1 2025), and SRD-003 (DMD-CM; IND cleared; first patient expected Q4 2024).